PDP1 and pulmonary arterial hypertension: Pharmacological activation of pyruvate dehydrogenase (PDH) via dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, has been shown to reverse PAH symptoms, underscoring that targeting mitochondrial metabolism directly ameliorates vascular hyperproliferation and apoptosis resistance in PAH (44).